Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

01-06-2020 | Breast Cancer | Letter to the Editor

Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life

Authors: Leonardo Ribeiro Soares, Victor Domingos Lisita Rosa, Ruffo Freitas-Junior

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Excerpt

We read with great interest the work of Gong et al. [1], which addressed the differences in clinical outcomes in women with HER2-positive metastatic breast cancer (MBC) conducted in clinical trials and in real life. In the population-based cohort, the overall survival observed in populations treated with trastuzumab/pertuzumab (39.2 months) and T-DM1 (15.4 months) was lower than that observed in the respective pivotal clinical trials (56.4 and 30.9 months, respectively). …
Literature
1.
2.
3.
Metadata
Title
Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life
Authors
Leonardo Ribeiro Soares
Victor Domingos Lisita Rosa
Ruffo Freitas-Junior
Publication date
01-06-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05659-6

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Preclinical study

Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study

Clinical trial

A prospective cohort study to analyze the interaction of tumor-to-breast volume in breast conservation therapy versus mastectomy with reconstruction

Clinical trial

Breast sensibility in bilateral autologous breast reconstruction with unilateral sensory nerve coaptation

Review

Healthcare providers’ adherence to breast cancer guidelines in Europe: a systematic literature review

Preclinical study

MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients

Epidemiology

Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits